

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

<p>High cost drugs excluded from the 2021-22 National Tariff are not commissioned by Mid and South Essex Clinical Commissioning Groups (CCGs) unless the drugs and indications have approval through local processes.</p>	
<p>Please note that the enclosed information reflects the current commissioning arrangements. These arrangements are subject to change in year if commissioning responsibility for particular drugs or services change between Mid and South Essex CCGs and the NHS England and/or new local drug policies are introduced or new NICE guidance is published.</p>	
<p>Any drug and/or indication (licensed or unlicensed use) not listed In Appendix 1 is designated as NOT COMMISSIONED</p>	
<p>The table in Appendix 1 summarise the policy on the commissioning of drugs and devices. It is coded by a "traffic light" scheme as follows:</p>	
	<p>Not commissioned. Where provider Trusts prescribe this treatment the funding responsibility lies with the provider and not the commissioner.</p>
	<p>Approved for use in line with NICE Guidance or where NICE has been converted into a locally agreed protocol or EoE CCG policy. Notification or individual or group prior approval required using proforma or electronic Blueteq® forms as per contract. Clinical evidence of outcomes may be requested by CCGs (in line with local contracts). Funding will not be authorised for patients who do not meet agreed criteria.</p>
	<p>Approved for use in line with locally agreed guidance only. Prior approval, notification proformas or electronic Blueteq® forms should be completed. Indications with other minimum dataset information must be provided on back up data to invoices.</p>
	<p>NHS England commissioning responsibility. CCGs should not consider funding requests for these drugs in these indications / group of patients. For drugs or indications where NHS England is the responsible commissioner the current version of the NHS England drug list should be referred to for the commissioning position, this is located at : https://www.england.nhs.uk/commissioning/spec-services/key-docs/</p>

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Adalimumab or biosimilar	13.5.3	Cytokine modulators	Psoriasis	NICE TA146 June 2008	In line with NICE TA146.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or biosimilar	1.5.3	Cytokine modulators	Crohn's Disease	NICE TA187 May 2010	In line with NICE TA187	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or biosimilar	10.1.3	Cytokine modulators	Psoriatic Arthritis	NICE TA199, August 2010	In line with NICE TA199.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Adalimumab or biosimilar	1.5.3	Cytokine modulators	Moderate to severe active ulcerative colitis after the failure of conventional therapy	NICE TA329 February 2015	In line with NICE criteria TA329	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or biosimilar	10.1.3	Cytokine modulators	Rheumatoid arthritis	NICE TA375 January 2016. (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC	In line with NICE criteria TA375 or TA195.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or biosimilar	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383 February 2016	In line with NICE TA383.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Adalimumab or biosimilar	10.1.3	Cytokine modulators	Axial spondyloarthritis (non- radiographic)	NICE TA383 February 2016	In line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or biosimilar	10.1.3	Cytokine modulators	Polyarticular juvenile idiopathic arthritis	NICE TA373 December 2015	In line with NICE TA373.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.
Adalimumab or biosimilar	10.1.3	Cytokine modulators	Moderate rheumatoid arthritis after conventional DMARDs have failed	NICE TA715 July 2021	In line with NICE TA715	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradenitis Suppurativa (NICE TA 392) and Bechet's syndrome.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Andexanet alfa	3.2	Factor Xa inhibitor antidote	Reversal of Factor Xa inhibition	NICE TA697 May 2021	In line with NICE TA697.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Baricitinib	10.1.3	Cytokine modulators	Moderate to severe active rheumatoid arthritis not to, or who are intolerant to one or more DMARDs.	NICE TA466 August 2017	In line with NICE TA466.	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use.
Baricitinib	10.1.4	Cytokine modulators	Atopic dermatitis in adults. Moderate to severe.	NICE TA681 March 2021	In line with NICE TA681	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected.
Brolucizumab	10.1.3	Cytokine modulators	Wet aged-related macular degeneration	NICE TA672 February 2021	In line with NICE TA672	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected
Crisaborole		Boron-based phosphodiesterase 4 inhibitor	Mild to moderate atopic dermatitis in people 2 years and older	NICE TA701 May 2021 Terminated appraisal	NOT COMMISSIONED	NOT COMMISSIONED	
Guselkumab	13.5.3	Drugs affecting the immune response.	Plaque psoriasis, moderate-to-severe	NICE TA521 June 2018	In line with NICE TA521	Complete proforma (using agreed local systems)	

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Guselkumab	13.5.3	Drugs affecting the immune response.	Active psoriatic arthritis after inadequate response to DMARDs	NICE TA711 June 2021	In line with NICE TA711	Complete proforma (using agreed local systems)	
Infliximab IV or biosimilar	1.5.3	Cytokine modulators	Crohn's Disease	NICE TA187, May 2010	In line with NICE TA187	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	Rheumatoid Arthritis	NICE TA195 August 2010 or NICE TA375 January 2016 (partial review of TA375, NICE ID2710. In development [GID-TA10586] Expected publication date: TBC	In line with NICE TA375 or TA195.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	Psoriatic Arthritis	NICE TA199, August 2010	In line with NICE TA199.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.
Infliximab or biosimilar	13.5.3	Cytokine modulators	Psoriasis (adults)	NICE TA134, January 2008	In line with NICE TA134.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.
Infliximab IV or biosimilar	1.5.3	Cytokine modulators	Ulcerative Colitis (acute exacerbations)	NICE TA163, December 2008	In line with NICE TA163.	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Infliximab or biosimilar	1.5.3	Cytokine modulators	Ulcerative Colitis - 2nd line for moderate to severely active	NICE TA329 Feb 2015	In line with NICE TA329	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	Ankylosing spondylitis	NICE TA383 February 2016	If treatment is started with the least expensive infliximab product in line with NICE TA383	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	Diarrhoea or colitis associated with Immune Checkpoint Inhibitor (unlicensed indication)	Local policy (PAC statement)	Only in line with Local Policies (PAC policy)	Complete proforma (using agreed local systems)	GP prescribing NOT expected. PAC recommendations published July 2019. NHS England are the responsible commissioner for use in paediatrics.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	JIA (unlicensed indication)	Patient currently responding to treatment.	Continuation and discontinuation in line with NHSE policy E03/P/d (EO3X04). No initiation in adults	Complete proforma (using agreed local systems)	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradentis suppurativa and Bechets syndrome.
Infliximab subcutaneous injection	13.5.3	Drugs affecting the immune response	Subcutaneous injection. Licensed indications - gastroenterologic and rheumatologic conditions.	No NICE guidance anticipated	NOT COMMISSIONED	NOT COMMISSIONED	
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	Axial spondyloarthritis (non- radiographic). Unlicensed indication.	Not considered in NICE TA383 February 2016.	NOT COMMISSIONED	NOT COMMISSIONED	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradentis suppurativa and Bechets syndrome.
Infliximab IV or biosimilar	10.1.3	Cytokine modulators	Moderate rheumatoid arthritis after conventional DMARDs have failed	NICE TA715 July 2021	In line with NICE TA715	Complete proforma (using agreed local systems)	CCG commission Adults only. GP prescribing NOT expected. NHS England is responsible commissioner for plaque psoriasis in children NICE TA 455, paediatric use (of adult TAs), uveitis (NICE TA 460) and Hidradentis Suppurativa (NICE TA 392) and Bechet's syndrome.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Infliximab IV or biosimilar	1.5.3	Cytokine modulators	Ulcerative Colitis (Sub acute manifestations)	NICE TA329 Feb 2015 Not recommended	NOT COMMISSIONED	NOT COMMISSIONED	CCG commission Adults only, GP prescribing NOT expected. NHS England is responsible commissioner for paediatric use, uveitis, connective tissue, interstitial lung disease, graft versus host, renal, sarcoidosis, hidradenitis suppurativa and Bechets syndrome.
Risankizumab		Humanised IgG1 Monoclonal antibody	Chronic plaque psoriasis moderate-severe	NICE TA 596 August 2019	In line with NICE TA 596	Complete proforma (using agreed local systems)	Adults only, GP prescribing NOT expected.
Risankizumab		Humanised IgG1 Monoclonal antibody	Psoriatic arthritis	NICE ID1399. Proposed [GID-TA10819] Expected publication date: TBC .	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch date 2021. It is anticipated that NHSE is responsible commissioner for paediatric use.
Risankizumab		Humanised IgG1 Monoclonal antibody	Crohn's disease	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch date 2022. It is anticipated that NHSE is responsible commissioner for paediatric use.
Risankizumab		Humanised IgG1 Monoclonal antibody	Ulcerative colitis	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	Predicted UK launch date 2024. It is anticipated that NHSE is responsible commissioner for paediatric use.

Appendix 1: Mid and South Essex CCGs Collaboration Commissioners' list of indications that may be commissioned for excluded drugs 2021/2022

Drug name	BNF section	Category	Licensed Indication/ Indication	NICE Guidance	Indications agreed for funding across EoE	Is this commissioned? What is required for funding approval?	Notes
Secukinumab	10.1.3	Cytokine modulators	Chronic plaque psoriasis moderate-severe after failed conventional therapies	NICE TA350 July 2015	In line with NICE TA350	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab	10.1.3	Cytokine modulators	Ankylosing spondylitis after treatment with non-steroidal anti-inflammatory drugs or TNF-alpha inhibitors	NICE TA407 September 2016	In line with NICE TA407	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab		Cytokine modulators	Psoriatic arthritis, second line	NICE TA455 May 2017	In line with NICE TA407	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab	10.1.3	Cytokine modulators	Axial - spondyloarthritis (non-radiographical)	NICE TA719 July 2021	In line with NICE TA719	Complete proforma (using agreed local systems)	Adults only. GP prescribing NOT expected. NHS England responsible commissioner for paediatric use but do not commission as unlicensed indication.
Secukinumab	10.1.3	Cytokine modulators	Psoriatic arthritis, axial manifestations	No NICE guidance anticipated.	NOT COMMISSIONED	NOT COMMISSIONED	
Vedolizumab Sub cut	13.5.3	Drugs affecting the immune response	Ulcerative colitis and Crohn's disease.	No NICE guidance anticipated	NOT COMMISSIONED	NOT COMMISSIONED	NHS England is responsible commissioner for paediatric use